Therapeutic Targets for the Treatment of Colorectal Cancer
A special issue of Gastrointestinal Disorders (ISSN 2624-5647).
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 10398
Special Issue Editor
Special Issue Information
Dear Colleagues,
Colorectal cancer (CRC) is the second leading cause of cancer mortality, responsible for about 900,000 deaths worldwide annualy. The 5-year survival rate of CRC patients is ~64%, but drops to ~12% for metastatic CRC. Treatment consists of surgery, and is combined with radio-, chemo- and targeted therapy for advanced CRCs. Targeted therapy is directed against proteins that drive tumor growth and progression. The advantage of targeted treatment is its ability to block the growth and spread of cancer cells while limiting damage to healthy cells. Today, therapies targeting EGFR and VEGF, as well as the immune-checkpoints have been approved for CRC treatment, while many more are in clinical or pre-clinical development. This special issue will focus on the identification and validation of therapeutic targets for CRC as well as on the development and management of therapeutic approaches for their inhibition. In addition, inovative therapeutic approaches to target currently undrugable proteins, such as synthetic lethality, aptamers, or targeted protein degradation will be discussed.
Dr. Matjaz Rokavec
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Gastrointestinal Disorders is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Colorectal cancer
- Therapeutic targets
- Targeted therapy
- Precision oncology
- Personalized treatment
- Metastasis
- EGFR
- VEGF
- Synthetic lethality
- Small molecules
- Biologics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
